Frequency Therapeutics

Frequency Therapeutics is a clinical-stage biotechnology company focused on leveraging the body's intrinsic biology to repair or reverse damage caused by a variety of degenerative diseases. Frequency Therapeutics develops small molecule drugs to activate progenitor cells within the body to restore healthy tissue. The initial therapeutic focus is on sensorineural hearing loss (SNHL), the most prevalent type of hearing loss. SNHL is typically caused by the permanent loss of sensory hair cells within the cochlea of the inner ear. FX-322, their lead product candidate, aims to regenerate hair cells by activating progenitor cells already present in the cochlea.